Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female engineer named Morgan Beller.Technologyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
The president also said he "offered to personally vouch" for Rocky's bail. Sweden, however, does not have a bail system.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people after coming under fire from politicians — but at the end of the day, its CEO told CNBC on Thursday she has a business to run.
"I'm running a business," Mylan's chief executive officer, Heather Bresch, said on "Squawk Box. " "We have over 600 products here in the United States that we got mid-single-digit erosion — decreases. No one was talking about price decreases, but that does happen in the industry to keep medicine affordable."
The price of the EpiPen, a lifesaving medication and delivery system for people with severe allergies, has increased more than 400 percent in the past decade, outraging many parents and prompting senators and Democratic presidential nominee Hillary Clinton to question the pricing process.
Before Bresch appeared on CNBC, the company announced it is reducing the cost of EpiPens through the use of a savings card that will cover up to $300 for the EpiPen 2-Pak. Patients who were previously paying the full price for the EpiPen will have their out-of-pocket cost cut by 50 percent. Mylan also is doubling the eligibility for its patient assistance program.
"The fight on the $300 billion pharmaceutical market is real, and we need to fix it, because it's not sustainable," Bresch said. "We are going to continue to run a business, and we are going to continue to meet the supply and demand that's out there."
Bresch said Mylan subsidizes EpiPens in many parts of the world, but it has invested resources into a broken health-care system in the U.S. and in raising patient awareness.
"We've put hundreds of millions of dollars behind it," Bresch said.